Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Y. Murata



Author of

  • +

    P3.06 - Poster Session 3 - Prognostic and Predictive Biomarkers (ID 178)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Biology
    • Presentations: 1
    • +

      P3.06-018 - ECT2 overexpression and gene alteration are associated with the outcome of early-stage lung adenocarcinoma (ID 1761)

      09:30 - 09:30  |  Author(s): Y. Murata

      • Abstract

      Background
      Background: In order to evaluate gene abnormality in lung adenocarcinoma at an early stage, genomic DNAs of six in situ adenocarcinomas (Ad) and nine small but invasive adenocarcinomas (INVAd) were examined by array-comparative genomic hybridization. Finally, 3q26 was detected as a significantly amplified region in INVAd relative to in situ Ad. Among the genes located at 3q26, we selected the epithelial cell transforming sequence 2 oncogene (ECT2) and examined it for abnormality in lung Ad, since ECT2 is related to Rho-specific exchange factors and cell cycle regulators, and is also thought to have an important role in the regulation of cytokinesis.

      Methods
      Methods: The clinical implications of ECT2 abnormality were examined by quantitative real-time genomic PCR (qPCR) and immunohistochemistry (IHC) using 158 cases of varies types of LAd, resected at Tsukuba University Hospital. The results were verified by cDNA microarray and 10k SNP array using another set of early-stage LAds, resected at the National Cancer Center Hospital.

      Results
      Results: qPCR and IHC analyses revealed overexpression of ECT2 in INVAd, and this was correlated with the MIB-1 index. ECT2 overexpression was significantly associated with lymph node metastasis, pathological stage, vascular invasion and the histological subtype of Ad. Patients with LAd overexpressing ECT2 showed an unfavorable outcome in terms of both disease-free and overall survival (Figure). These results were verified using another set of 144 early-stage Ads resected at the National Cancer Center Hospital. Figure 1

      Conclusion
      Conclusion: ECT2 is a new marker that can be used for prognostication of patients with early-stage LAd.